Dominic J A, Miller R E, Anderson J, McAllister R G
Pharmacology. 1980;20(4):196-202. doi: 10.1159/000137365.
The effect of verapamil on glucose tolerance and insulin release in conscious, healthy dogs was studied at plasma drug concentrations which produce therapeutic cardiovascular effects. Plasma glucose and immunoreactive insulin were measured serially in each animal for 90 min after an intravenous glucose challenge (400 mg/kg), both during a control study and again during administration of verapamil. The drug was given by infusion protocols to produce plasma concentrations at low (84 +/- 9 ng/ml), intermediate (161 +/- 30 ng/ml), and high (367 +/- 51 ng/ml) ranges. Insulin release was impaired and glucose levels elevated at both the intermediate and the high verapamil concentrations, and to a similar degree. The reduction in insulin release and subsequent increase in plasma glucose is a pharmacologic effect of verapamil which occurs at drug concentrations likely to be achieved during clinical use.
在清醒健康犬体内，于产生治疗性心血管效应的血浆药物浓度下，研究了维拉帕米对葡萄糖耐量和胰岛素释放的影响。在对照研究期间以及维拉帕米给药期间，对每只动物在静脉注射葡萄糖（400mg/kg）后连续90分钟测量血浆葡萄糖和免疫反应性胰岛素。通过输注方案给予该药物，以产生低（84±9ng/ml）、中（161±30ng/ml）和高（367±51ng/ml）范围的血浆浓度。在维拉帕米的中、高浓度下，胰岛素释放均受损，血糖水平升高，且程度相似。胰岛素释放减少及随后血浆葡萄糖升高是维拉帕米的一种药理效应，该效应发生在临床使用中可能达到的药物浓度下。
